LETTER

EULAR points to consider for including the perspective of young patients with inflammatory arthritis into patient-reported outcomes measures

Paul Studenic 1,2 Tanja A Stamm 3,4 Erika Mosor 3,4 Ilaria Bini 5,6 Nele Caeyers 7 Laure Gossec 8 Marios Kouloimas 3,10 Elena Nikpiorou 8 Simon Stones 7,17 Tanita-Christina Wilhelmer 6,18 Alessia Alunno 19,20

A range of patient-reported-outcome measures (PROMs) with different features is available for people with inflammatory arthritis (IA). However, the needs and priorities of young people (aged 18–35 years) with IA regarding PROMs and their administration have never been systematically explored. Therefore, our project tackled the question whether PROMs commonly used in IA cover the perspectives and needs of young people. For this purpose, a task force (TF) guided by the 2014 EULAR Standardised Operating Procedures was convened. Given the limited literature on the perspectives of young people with IA regarding PROMs, a multinational focus group study and a subsequent online survey distributed across Europe replaced the conventional systematic literature review (online supplemental figure S1). The EULAR Council approved this research-based project approach. The TF was composed of 14 members from 8 European countries, with a strong representation of patient research partners. The TF met twice and, based on the results of the focus groups and survey, formulated four overarching principles (OPs), 8 points to consider (PtC) (table 1) and a research agenda (online supplemental table S1). Every TF member indicated agreement with a PtC or OP by formal voting (yes/no/abstain) during the second meeting and then anonymously scored their level of agreement (Numerical Rating Scale ranging from 0=no agreement to 10=absolute agreement) after the meeting in a subsequent email round. The OPs and PtC focused on the preferences of young patients with IA regarding the value of PROMs for shared decision making and monitoring, their content and mode of administration.

These EULAR PtC provide the first guidance to optimise the use of available PROMs for young people with IA. They should also serve as a companion for clinicians and researchers in rheumatology practice, and the relevant stakeholders when developing new PROMs and modifying existing PROMs. The OPs formulated by the TF underpin the value of PROMs as key elements to assess the impact of IA on the daily life of young people with IA, to aid the shared decision-making process. The PtC encompass several areas such as information/education on PROMs, their purpose and the use of their results (PtC 1–3), daily life activities relevant to young people (PtC 4–6) and the use of technology for health-related purposes (PtC 8). Some PtC might be applicable to young patients and to patients aged above 35 years. However, despite these potential similarities, the PtC presented were developed from the needs and priorities identified by young people with IA regarding PROMs. Therefore, clinicians and researchers should strive to consider and embed the perspective of young people in the development of PROMs, to pave the way for a more inclusive, individualised and equal assessment of health, disease activity and well-being.

In summary, these are the first PtC for the use of PROMs in young patients with IA based on their own perspectives. We believe that the optimisation and harmonisation of PROMs used in daily practice could strengthen the relationship between patients and healthcare providers, facilitating shared decision making.
Table 1 Overarching principles and points to consider for including the perspective of young patients with IA into PROMs

<table>
<thead>
<tr>
<th>Overarching principles</th>
<th>LoA Mean (SD)</th>
<th>Points to consider</th>
<th>LoE</th>
<th>Strength of recommendation</th>
<th>LoA Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A IA has a considerable impact on all aspects of the life of young people, and PROMs are useful to measure part of this impact</td>
<td>9.69 (±0.63), 100%≥8</td>
<td>1 Young people with IA should be informed about the purpose and relevance of PROMs.</td>
<td>5</td>
<td>D</td>
<td>9.85 (0.37), 100%≥8</td>
</tr>
<tr>
<td>B The value of PROMs is optimised when young people with IA are informed and empowered</td>
<td>9.92 (0.28), 100%≥8</td>
<td>2 Young people with IA should have the possibility to access their personal PROM data.</td>
<td>5</td>
<td>D</td>
<td>9.31 (1.18), 85%≥8</td>
</tr>
<tr>
<td>C PROMs are useful when integrated in the communication between young people with IA and rheumatologists/other health professionals who are involved in their care.</td>
<td>9.77 (0.44), 100%≥8</td>
<td>3 Healthcare providers and young people with IA should discuss the results of PROMs and integrate them into shared decision making.</td>
<td>5</td>
<td>D</td>
<td>9.78 (0.44), 100%≥8</td>
</tr>
<tr>
<td>D PROMs inform shared decision-making for young people with IA.</td>
<td>9.31 (0.18), 92%≥8</td>
<td>4 Different PROMs assess various domains and should therefore be used to cover a broad spectrum of the disease.</td>
<td>5</td>
<td>D</td>
<td>9.15 (1.82), 85%≥8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 Healthcare providers should ascertain the willingness of young people with IA to talk about issues such as body image and life plans, and discuss these domains respecting the patients’ preferences.</td>
<td>5</td>
<td>D</td>
<td>9.54 (1.13), 92%≥8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 The assessment of a young person with IA should encompass items and domains of his/her daily life such as psychosocial issues, participation in social activities, education/work, sports and using technologic devices.</td>
<td>5</td>
<td>C</td>
<td>9.46 (1.20), 92%≥8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7 The schedule of PROMs assessment should be agreed on by the healthcare provider and the young person with IA, to balance frequency versus inconvenience.</td>
<td>5</td>
<td>D</td>
<td>9.46 (1.05), 92%≥8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8 Online and e-solutions for PROMs should be used when possible and convenient for young people with IA.</td>
<td>5</td>
<td>D</td>
<td>9.92 (0.28), 100%≥8</td>
</tr>
</tbody>
</table>

Numbers in the column ‘LoA’ indicate the mean (SD) of the LoA, and the percentage of task force members with a LoA of at least 8 (0–10); based on the Oxford Centre for Evidence-Based Medicine classification.

IA, inflammatory arthritis; LoA, level of agreement; LoE, level of evidence; PROMs, patient-reported outcome measures.

making, and ultimately, the quality and experience of care for young people with IA.

Author affiliations
1Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Wien, Austria
2Department of Medicine (Solna), Division of Rheumatology, Karolinska Institute, Stockholm, Sweden
3Ludwig Boltzmann Institut für Arthritis und Rehabilitation, Wien, Austria
4Section for Outcomes Research, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria
5Anmar Young, Rome, Italy
6EULAR Young PARE, Zurich, Switzerland
7EULAR PARE, Zurich, Switzerland
8INSERM, Institut Pierre Louis d’Épidémiologie et de Santé Publique, INSERM, Sorbonne Université, Paris, France
9AP-HP; Sorbonne Université, Rheumatology department, Hospital Universitaire Pitie Salpetriere, Paris, France
10Cyprus League Against Rheumatism, Aglaiztia, Cyprus
11Centre for Rheumatic Diseases, King’s College London, London, UK
12Rheumatology Department, King’s College Hospital, London, UK
13Youth-R-Well, Nieuwegein, The Netherlands
14Department of Internal Medicine, Division of Clinical Immunology and Rheumatology, University Hospital Centre Zagreb, Zagreb, Croatia
15Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
16Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands
17Envision Pharma Group Limited, Wimstow, UK
18Österreichische Rheumaliga, Maria Alm, Austria
19Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy
20Internal Medicine and Nephrology Unit, Department of Medicine, ASL Avezzano-Sulmona-L’Aquila, San Salvatore Hospital, L’Aquila, Italy

Twitter Paul Studenic @Stiddyo, Marios Kouloumas @kouloumasm, Elena Nikiphorou @ElenaNikiUK, Ivan Padjen @ivan_padjen and Simon Stones @SimonRStones

Acknowledgements This manuscript was reviewed and approved by all TF members and ratified by the EULAR Council. We would like to thank the focus group and survey participants for sharing their valuable perspectives. TF members are also grateful to EULAR PARE, Young PARE and EMEUNET for their support throughout the entire project.

Contributors All authors contributed to the work leading to the manuscript. The manuscript was drafted by PS and AA and revised and reviewed by all authors.

Funding This project was funded by the European Alliance of Associations for Rheumatology (EULAR), grant number CL1100.

Competing interests PS, TAS, EM, JB, NC, MK, EN, WD, JP, TW-CW and AA; nothing to disclose. LGc: Personal fees from AbbVie, Amgen, Biogen, Celgene, Gilead, Janssen,
Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; grants from Lilly, Pfizer, and Sandoz, outside the submitted work. Sofia Ramiro: consultancy and/or speaking fees from AbbVie, Eli Lilly, MSD, Novartis, Sanofi and UCB. SS: employment by Envision Pharma Group; stock options in Envision Pharma Group; consultancy and/or speaking fees from 67 Health, Ampersand Health, Envision Pharma Group, Janssen, On The Pulse Consultancy, Parexel and Sheffield Hallam University.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; internally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

**ORCID iDs**

Paul Studenic http://orcid.org/0000-0002-8895-6941
Tanja A Stamm http://orcid.org/0000-0003-3073-7284
Erika Mosor http://orcid.org/0000-0003-4293-0647
Laure Gossec http://orcid.org/0000-0002-4528-310X
Elena Nikiphorou http://orcid.org/0000-0001-6847-3726
Sofia Ramiro http://orcid.org/0000-0002-8899-9087

Alessia Alunno http://orcid.org/0000-0003-1105-5640

**REFERENCES**